Becaris
Browse

Supplementary tables: Impact of the COVID-19 pandemic on healthcare resource utilization across selected disease areas in the USA

Download (39.41 kB)
dataset
posted on 2024-05-03, 13:50 authored by Kayla Engelbrecht, Srinjoy Roy, Gorana Capkun, Kristijan Kahler, Melvin Olson

These are peer-reviewed supplementary materials for the article 'Impact of the COVID-19 pandemic on healthcare resource utilization across selected disease areas in the USA' published in the Journal of Comparative Effectiveness Research.

  • Supplementary Table 1: Pharmaceutical disease cohorts' characteristics
  • Supplementary Table 2: Oncology disease cohorts' characteristics
  • Supplementary Table 3: Disease areas and ICD-10 clinical modification diagnosis codes
  • Supplementary Table 4: Total pre-pandemic and pandemic outpatient visits and the percentage change in outpatient visits for each disease area
  • Supplementary Table 5: Total pre-pandemic and pandemic inpatient visits and the percentage change in inpatient visits for each disease area
  • Supplementary Table 6: Total pre-pandemic and pandemic ED visits and the percentage change in ED visits for each disease area

Aim: To analyze the impact of the COVID-19 pandemic on US healthcare resource utilization. Methods: Optum claims data were used to compare all-cause healthcare visits and healthcare spending for selected diseases between the prepandemic and pandemic periods. Telemedicine use was only assessed for the pandemic period owing to data availability. Results: During the first wave of the pandemic, all-cause healthcare visits across all selected disease areas displayed a rapid decline compared with the prepandemic period, followed by a period of recovery. A reduction in outpatient and home healthcare spending was observed, whereas inpatient and prescription spending increased. Conclusion: Changes in healthcare resource utilization trends were observed during the pandemic. The magnitude of these changes can inform subsequent studies that utilize COVID-19-era data.

Funding

Development of this manuscript was funded by Novartis Pharma AG.

History

Usage metrics

    Becaris

    Categories

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC